Silence Therapeutics plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SLNCF | ADRX | 2257.HK | BNTC | PHM.MC | SRPT | |
|---|---|---|---|---|---|---|
| Market cap | — | 1.66B | 463.71M | 323.77M | 1.16B | 2.01B |
| P/E (TTM) | — | — | — | — | 17.1 | — |
| Forward P/E | — | -9.9 | — | -1.0 | 13.6 | 7.8 |
| Price/book | — | -0.7 | -9.5 | 1.8 | 4.9 | 1.3 |
| Dividend yield | — | — | — | — | 1.50% | — |
| 1-year change | — | −22.69% | −50.06% | −22.67% | −9.32% | +7.65% |
| Today | +2.36% | −7.02% | −0.12% | +10.48% | +0.60% | +2.43% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SLNCF news ›Silence Therapeutics (NASDAQ:SLN) & Connect Biopharma (NASDAQ:CNTB) Critical Survey
Posted by Kim Johansen on Oct 28th, 2026 Connect Biopharma (NASDAQ:CNTB – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will…
Silence Therapeutics plc (OTCMKTS:SLNCF) Stock Short Interest Drops 94.2%
Posted by Danessa Lincoln on Oct 28th, 2026 Silence Therapeutics plc (OTCMKTS:SLNCF – Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 136 shares, a…
Recent Analysts’ Ratings Changes for Silence Therapeutics (SLN)
Posted by Sarita Garza on Oct 27th, 2026 Silence Therapeutics (NASDAQ: SLN) recently received a number of ratings updates from brokerages and research firms: Silence Therapeutics plc is a clinical-stage biotechnology company focused on…
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
lincolnjournal.com Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (âKSFâ) are inve
Merck to Acquire Silence Therapeutics for $1.3 Billion, Expanding Rare Disease Portfolio with siRNA Innovation
21 October 2026 | Wednesday | News Merck, a leading science and technology company, announced its entry into a definitive agreement to acquire Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company…
Merck turns up the volume on rare disease with $1.3bn Silence Therapeutics buy
Germany’s Merck has agreed to acquire London-based Silence Therapeutics in an all-cash deal, adding a late-stage rare blood cancer asset to its pipeline. Shareholders of Silence Therapeutics will receive $20.00 per American Depositary…
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Published on 10/19/2026 at 08:45 am EDT Germany's Merck KGaA said it agreed to buy U.K. biotech company Silence Therapeutics for $1.3 billion, adding an experimental medicine for rare disease polycythemia vera to its drug pipeline. Merck…
More from 4 other outlets
- european-biotechnology.com Merck to buy siRNA specialist Silence Therapeutics for $1.3 billion
- Briefs Finance Merck KGaA agrees to buy Silence Therapeutics for roughly $1.1 billion
- PYMNTS.com Merck to Buy Silence Therapeutics for $1.3 Billion in RNA Drug Push
- PharmExec Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion.
Merck KGaA entered into definitive agreement to acquire Silence Therapeutics plc for $1.2 billion on October 18, 2026. The purchase price of $20 per ADS in cash, with each ADS representing three... Merck KGaA (XTRA:MRK) entered into…
Merck KGaA to Spend $1.3bn on Silence Therapeutics
Merck KGaA (-0.83%, at EUR143.10) announced that it has signed a definitive agreement to acquire British biotechnology company Silence Therapeutics, which specializes in developing therapies based on small interfering RNAs (siRNAs). The…
More from 1 other outlet
Shh! Silence Therapeutics is International Biotechnology’s ninth portfolio bid this year after Merck splashes $1.3bn
Silence Therapeutics, one of the few UK-based holdings of International Biotechnology Trust (IBT), has been acquired by German drugs giant Merck for $1.3bn cash. News of the agreed deal yesterday saw Silence’s US Nasdaq-listed shares soar…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com15
- themarketsdaily.com6
- stocktitan.net4
- seekingalpha.com2
- biopharmaapac.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 46 articles, not a forecast.